AGT and myasthenia gravis: Urinary and plasma angiotensinogen (AGT) levels were significantly lower in the MG-treated group: MG vs. control, 2.1 ± 0.2 vs. 3.2 ± 0.3 ng/mL (p = 0.014), 16.3 ± 6.7 vs. 29.3 ± 6.9 ng/day (p = 0.034), respectively.